Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 11/20 | 0.51 |
| ▸ | TP53 | P04637 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3284662 | 0.87 | LMNA (0.54) | LMNATP53MAPTPOLBALDH1A1 | |
| SCHEMBL13326796 | 0.87 | LMNA (0.54) | LMNATP53MAPTPOLBALDH1A1 | |
| SCHEMBL13632177 | 0.82 | TP53 (0.46) | LMNATP53POLBF10 | |
| SCHEMBL13632166 | 0.81 | LMNA (0.48) | LMNATP53POLBF10 | |
| SCHEMBL4492812 | 0.80 | TP53 (0.44) | LMNATP53POLBF10 | |
| SCHEMBL4503744 | 0.80 | F10 (0.49) | LMNATP53MAPTPOLBALDH1A1 | |
| SCHEMBL3292865 | 0.79 | F10 (0.55) | LMNATP53POLBF10 | |
| SCHEMBL5469178 | 0.78 | TP53 (0.45) | LMNATP53POLB | |
| SCHEMBL4512579 | 0.78 | F10 (0.48) | LMNATP53MAPTPOLBF10 | |
| SCHEMBL4505244 | 0.78 | LMNA (0.44) | LMNATP53F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7714000-B2 | Substituted pyrrolidinones and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| US-7714000-B2 | Substituted pyrrolidinones and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| US-7714000-B2 | Substituted pyrrolidinones and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| US-20060217435-A1 | New Substituted Pyrrolidinones and Their Use as Medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217435-A1 | New Substituted Pyrrolidinones and Their Use as Medicaments | PYCR1, S100A9, REV1 | LMNA 1767/4885TP53 3318/4885MAPT 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.